|
Abstract
|
Most B-cell-related disorders can be cured with conventional agents; however, relapse is common,
creating a need for additional therapeutic options. In agreement, recent biomarker studies corroborate
the role played by functional crosstalk between malignant B cells and microenvironment
which have added texture to clinical outcome. Here we outline the essential role of the tumorassociated
niche in B-cell Lymphoma/Leukemia pathogenesis, in an attempt to optimize the use of
microenvironment-targeted drugs and anti-CD20 antibodies in the various subsets.
|